Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A
Timeframe: From enrollment to the Follow-Up Visit 7 days post-discharge
Part B
Timeframe: From enrollment to the Follow-Up Visit 7 days post-discharge]
Part C
Timeframe: From enrollment to the Follow-Up Visit 7 days post-discharge]
Part D:
Timeframe: From enrollment to the Follow-Up Visit 7 days post-discharge
ORX489 Centessa Program Lead ORX489 Centessa Program Lead